Regenyx Medical Ltd.

Regenyx Medical Ltd. Overview

Regenyx Medical is redefining minimally invasive soft tissue restoration—a cornerstone of plastic and reconstructive surgery. Our lead product, Lipogenyx, is the first fat viability extender: a next-generation fat grafting solution that enhances graft survival and integration, enabling natural-looking, lasting and predictable results in reconstructive and aesthetic procedures. Built on a proprietary synthetic peptide hydrogel technology, Lipogenyx offers a scalable, potentially reimbursable platform that eliminates the need to revision fat grafting procedures and streamlines physicians efficiency and patient satisfaction. Selected for the 2025 MedTech Innovator and ASPS Top 5 Innovation Track, Regenyx is now preparing for its first clinical study and establishing U.S. operations.

Cumulative Funding Raised Over Time ($)

Latest News

Jun 13, 2025 · www.plasticsurgery.org

growth-positive

Five Plastic Surgery Startups Selected for MTI/ASPS Plastic Surgery Accelerator Competition Finals

MedTech Innovator, in partnership with the American Society of Plastic Surgeons (ASPS), has advanced five startups as finalists in the 2025 MedTech Innovator competition. These startups, which focus on medical device, diagnostic, and digital health technology, will compete for a share of $800,000 in funding awards. The program aims to foster innovation in plastic surgery by providing mentorship and support to early-stage companies. The finalists will be featured at an upcoming event in New Orleans and will receive guidance from ASPS surgeons and industry leaders. MedTech Innovator has a history of supporting over 500 companies, resulting in significant FDA approvals and funding.

Partners

Jun 5, 2025 · medtechinnovator.org

growth-positive

MedTech Innovator Unveils 64 Breakthrough Medtech Startups in its 2025 Cohort - MedTech Innovator

MedTech Innovator (MTI), the worlds largest accelerator for medical technology startups, announced its 2025 Accelerator Cohort, selecting 64 companies from nearly 1,500 global applicants. These companies will participate in a four-month program offering mentorship, strategic guidance, and access to MTIs ecosystem of industry leaders. The cohort includes early and mid-stage medical device, diagnostic, and digital health companies competing for $800,000 in non-dilutive funding. MTIs program aims to de-risk innovation and accelerate U.S. market success. The accelerator includes specialty tracks in partnership with the American Society for Plastic Surgeons and the American Heart Association. MTIs founding sponsors include Johnson & Johnson MedTech and Research Corporation Technologies, with additional support from various industry leaders.

May 15, 2019 · in.bgu.ac.il

growth-positive

Bone Sci Bio Presents Breakthrough Solutions for Bone Healing

Bone Sci Bio introduces PeptOss, a novel solution for bone treatment that promotes bone regeneration and enables controlled drug delivery. The company will present its product at the MIXiii-BIOMED 2019 Conference and Exhibition. PeptOss has various applications in orthopedic and dental medicine, including treating peri-implantitis and strengthening osteoporotic bones. The technology was patented by BGN Technologies. In pre-clinical trials, PeptOss has shown promising results, outperforming the control by up to 80%. Bone Sci Bio aims to gain FDA approval and address the unmet need in peri-implantitis treatment.

CustomersPartners

May 14, 2019 · www.timesofisrael.com

growth-positive

Israeli startup seeks to boost bone renewal and allow targeted drug delivery

Israeli startup Bone Sci Bio Ltd. is developing PeptOss, a product that promotes bone formation and repair while enabling controlled drug delivery. The product has applications in orthopedic and dental medicine, including the treatment of peri-implantitis and osteosarcoma. PeptOss is made up of a proprietary peptide that mimics bone proteins and self-assembles as a hydrogel. The technology has shown promising results in pre-clinical trials. The company estimates the bone substitute market to be worth $4.5 billion. Clinical studies and FDA approval are still pending.

Customers

Funding

Team Members

3

Employees: 1-10

Web & Social Links

Locations

Prof. A. D. Bergman St 2, Rehovot, Israel

Photos & Videos

2 item(s)

Regenyx Medical Ltd. Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info